Compugen’s CGEN-15001 recombinant fusion protein abolishes off the cuff relapses in savage facsimile of MS
Compugen Ltd. (NASDAQ:CGEN) announced today that dispensation of CGEN-15001 in an mammal shape of multiple sclerosis (MS) has been shown to in full obliterate impromptu relapses. In appendix, furnishing of this new molecule earlier to disorder inception demonstrated a clear wait of contagion start and a noteworthy de-escalation in illness symptoms. These results, together with complementary results from earlier studies, strongly brook a suggestive possibility salubrious utility pro CGEN-15001 in the treatment of multiple sclerosis and other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, traitorous bowel plague, and keyboard 1 diabetes.
CGEN-15001 is a soluble recombinant fusion protein comprised of the extracellular tract of a Compugen discovered B7/CD28 kinsmen colleague, designated CGEN-15001T. CGEN-15001T, which itself has implicit medical utilities – such as serving as a butt in behalf of antibody therapeutics – was discovered close Compugen throughout the usage of its LEADS podium and a proprietary algorithm designed to augur new members of known protein families. Patents require been filed in the direction of both CGEN-15001 and CGEN-15001T.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
